Evidence map›Paper›PMID 41564118›Full record

ArticlePloS one2026

Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.

Hua Li, Alexander Pemov, Robert Allaway, David F Muir, Lung-Ji Chang, Jineta Banerjee, Alexandra J Scott, Jaime M W Nagy, Jian Liu, Meritxell Carrió and 11 more

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Hua LiDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States of America.
Alexander PemovClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America.ORCID https://orcid.org/0000-0003-3893-3685
Robert AllawaySage Bionetworks, Seattle, Washington, United States of America.
David F MuirDepartment of Pediatrics, Division of Neurology, University of Florida, Gainesville, Florida, United States of America.
Lung-Ji ChangShenzhen Geno-immune Medical Institute, Shenzhen, China.
Jineta BanerjeeSage Bionetworks, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0002-1775-3645
Alexandra J ScottSage Bionetworks, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0002-1930-9265
Jaime M W NagyStead Family Department of Pediatrics, University of Iowa, Lowa City, Iowa, United States of America.
Jian LiuDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Meritxell CarrióGermans Trias i Pujol Research Institute, Badalona, Barcelona, Spain.
Helena MazuelasGermans Trias i Pujol Research Institute, Badalona, Barcelona, Spain.
Anthony YachnisDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, Florida, United States of America.
Sang Y LeeDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0003-3911-8316
Xiaochun ZhangDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Yang LyuDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Douglas R StewartClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America.ORCID https://orcid.org/0000-0001-8193-1488
Angela HirbeDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.ORCID https://orcid.org/0000-0003-1719-0771
Jaishri O BlakeleyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Eduard SerraGermans Trias i Pujol Research Institute, Badalona, Barcelona, Spain.
Deeann WallisDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Margaret R WallaceDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States of America.ORCID https://orcid.org/0000-0002-5202-8895

Funding

Clinical/Genetic Studies of Family/Hereditary CancersZ01CP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GREENE, MARK H · 2000 to 2008
$1.1M
Intramural NIH HHS Z01 CP010144
6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant condition in which patients are heterozygous for a disruptive pathogenic variant in the NF1 gene. The most characteristic feature of the condition NF1 is the neurofibroma, a benign, multi-cellular tumor which initiates when a cell of the Schwann cell lineage gains a somatic pathogenic variant of the other NF1 allele. Neurofibromas developing at nerve termini in the skin are termed "cutaneous" neurofibromas (cNFs), while those developing within larger nerves are termed "plexiform." Most patients develop cNFs beginning in late childhood or early adulthood, continuing throughout life at variable rates. Some patients may develop only a few cNFs, while others suffer from thousands. There are no reliably effective physical or pharmaceutical therapies besides surgical removal. Although these are not life-threatening, they are disfiguring and can interfere with normal life functions. To provide a resource for research, we developed short-term cNF Schwann cell cultures from NF1 patients, from which we subsequently established the first semi-immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes. Here we present molecular, cellular, and functional characterization of these cell lines, which will be of utility for investigating and developing NF1 cNF therapies.

Indexed as

NeurofibromaNeurofibromatosis 1Schwann CellsSkin NeoplasmsAnimalsCyclin-Dependent Kinase 4HumansMiceNeurofibromin 1TelomeraseCyclin-Dependent Kinase 4Neurofibromin 1TelomeraseTERT protein, human

Identifiers

PMID41564118
PMCPMC12822933

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.